-
Novo’s CagriSema Was Associated with 25% Weight Loss on Average for Women in a Post Hoc Analysis of REDEFINE 1
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 20, 2026 /PRNewswire/ — Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of… Source: Read More
-
CagriSema vs. Tirzepatide: Insights from the REIMAGINE 5 Trial
A New Frontier in Weight Management The landscape of obesity treatment is evolving rapidly, and recent data from the REIMAGINE 5 trial has provided a compelling look at the next generation of weight-loss therapies. Novo Nordisk has shared results comparing their investigational drug, CagriSema, directly against tirzepatide (marketed as Zepbound/Mounjaro), marking a significant milestone in…
-
CagriSema: The Breakthrough Combo Targeting ‘Food Noise’ and Metabolic Health
A New Frontier in Weight Management Recent clinical updates regarding CagriSema, an investigational drug developed by Novo Nordisk, are generating significant buzz in the medical community. This once-weekly injectable treatment combines semaglutide with cagrilintide, offering a dual-action approach to treating obesity and type 2 diabetes. Silencing ‘Food Noise’ One of the most compelling aspects of…